New research data for Multiple Sclerosis 57
According metin Medical Association of Athens.
Important new data from the recent 66th Annual Meeting of the American Academy of Neurology (AAN), and the opinion in favor of enlargement of the indication of fingolimod, announced at a press conference held by the Medical Association of Athens.
The experience of more than 91 500 patients worldwide, already tracked up to 10 years, confirming the safety profile of fingolimod in clinical practice. The fingolimod is the only oral disease-modifying therapy that acts on four key measures of disease activity Multiple Sclerosis (MS) relapses, failures according to MRI, reduction in brain volume and worsening disability. The enlargement of the display and the possibility for patients to receive fingolimod regardless of their initial therapy, proves the confidence of the European Medicines Agency on the safety of the product.
Nicholas Fakas, Chief Medical Officer - Director of the Neurology Clinic 401 GNS said that "in recent years the therapeutic range of Multiple Sclerosis (MS) expanded with the introduction of new treatment options, but principally by better understanding the mechanisms of disease. Plus monitor disease activity on four criteria, namely relapses, the outbreaks in magnetic, disability and brain atrophy. The possibility of therapeutic intervention with most treatments are effective on all four indicators, such as fingolimod, is an important weapon in the hands of doctors. "
Additionally, the presentation of new data on the 66th Annual Meeting of the American Academy of Neurology (AAN) indicate that fingolimod slow the pace of reduction in brain volume in patients with Multiple Sclerosis. Specifically, the evidence presented showed that a significantly greater number of patients treated with fingolimod (versus patients receiving placebo) showed reduction rates of brain tumor, comparable with healthy subjects without MS.
All people have been decreasing brain volume as they grow (also called shrinkage of the brain or cerebral atrophy), but people with MS show shrinkage of the brain up to three to five times faster. This acceleration starts early in people with relapsing MS, even before symptoms become apparent. Under ever increasing evidence, damage from injuries and the reduction of brain tumor leads to a worsening of the symptoms of MS (e.g. gait problems or difficulties in cognitive tasks). Moreover, the reduction of brain volume is closely linked to long-term disability.
Share This Article With Your Friends...
Article Discussion ...
iii) Please don't use any offensive words in comments, don't abuse or spam
Check here Comments Policy and Terms